Education
About Us
Working with TipRanks
Follow Us
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
Top Page
Tarsus Pharmaceuticals
(NASDAQ:TARS)
Select Model
Select Model
Rating:62Neutral
Price Target:
$80.00
▲(5.93% Upside)
Action:ReiteratedDate:02/25/26
The score is driven primarily by improving financial fundamentals (rapid revenue growth, very high gross margins, and a de-risked balance sheet) and a constructive earnings call with strong 2026 growth guidance. Offsetting these positives are continued losses and cash burn (weak cash flow profile) and limited valuation support due to a negative P/E, while technical signals are positive but not fully confirmed.
Positive Factors
Accelerating revenue with very high gross margins
Rapid top-line growth combined with unusually high product-level gross margins provides durable unit economics. High gross margins give room to absorb SG&A/R&D while scaling, enabling operating leverage as distribution and refill rates improve toward steady state.
De-risked balance sheet and meaningful cash runway
Elimination of debt and a substantial cash balance materially reduce financing risk for the next 2–6 months. This funding supports commercialization investments and planned Phase II programs without near-term dilution, allowing focus on execution rather than emergency financing.
Commercial traction and large addressable market
Low current penetration vs. a large target population and rapid awareness gains support a multi-year growth runway. Product-line profitability and ambitious 2026 guidance (~50% growth) reflect scalable commercial adoption and sustainable demand expansion if refill behavior improves.
Negative Factors
Negative operating and free cash flow
Despite improvement, persistent negative operating and free cash flow means the business is not yet self-funding. Continued cash burn creates financing overhang risk if revenue growth slows or marketing/R&D spend needs to accelerate to hit targets.
Company-level unprofitability driven by high operating expenses
Very large SG&A and R&D spend relative to current sales constrains near-term company profitability. Even with strong margins, the need to fund aggressive commercial expansion and clinical programs delays enterprise-level positive earnings until operating leverage materializes.
High gross-to-net and reliance on new-patient growth
A sustained ~43–45% gross-to-net discount materially lowers realized revenue per unit. Reliance on new-patient acquisition and below-target refill rates creates sensitivity to seasonality, access issues and payer dynamics, slowing durable margin conversion.
Tarsus Pharmaceuticals (TARS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.21B
Dividend YieldN/A
Average Volume (3M)631.80K
Price to Earnings (P/E)―
Beta (1Y)0.31
Revenue Growth182.44%
EPS Growth47.21%
CountryUS
Employees323
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.20
Shares Outstanding42,557,490
10 Day Avg. Volume837,177
30 Day Avg. Volume631,804
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)9.96
Price to Sales (P/S)7.58
P/FCF Ratio-153.35
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue6.90
Enterprise Value/Gross Profit7.70
Enterprise Value/Ebitda-55.76
Forecast
1Y Price Target
$91.57Price Target Upside21.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.51
Revenue Forecast (FY)$668.48M
Tarsus Pharmaceuticals Business Overview & Revenue Model
Company DescriptionTarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
How the Company Makes MoneyTarsus Pharmaceuticals generates revenue primarily through the development and commercialization of its pharmaceutical products. The company's revenue model is centered around bringing its lead product, TP-03, to market, which includes potential sales from prescriptions once it receives regulatory approval. Furthermore, Tarsus may engage in strategic partnerships with larger pharmaceutical companies for co-development and commercialization agreements, which can provide upfront payments, milestone payments, and royalties on future sales. The company may also generate revenue through grants or funding from research initiatives. As it advances its clinical programs and potentially secures regulatory approvals, Tarsus aims to establish a stream of income through direct product sales and collaborations.
Tarsus Pharmaceuticals Earnings Call Summary
Earnings Call Date:Feb 23, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call communicated a strongly positive commercial trajectory for XDEMVY—robust 2025 performance, bold 2026 guidance (+~50% at midpoint), expanding awareness and payer coverage, product-line profitability, and a funded pipeline with near-term clinical catalysts for TP-04 and TP-05. Offsetting these positives are material near-term expense levels, a high gross-to-net discount (~43%-45%), Q1 seasonality headwinds and reliance on new-patient driven growth until refill rates stabilize. Overall, the company presents clear growth momentum but must demonstrate operating leverage and sustained margin conversion to fully realize its $2B+ peak sales ambition.Q4-2025 Updates
Positive Updates
Strong 2025 Revenue Performance
Full-year 2025 net product sales of $451.4 million and Q4 2025 net product sales of $151.7 million, demonstrating rapid commercial traction since launch.
Ambitious 2026 Guidance and Rapid Growth
Provided first-ever full-year 2026 guidance of $670M to $700M in net product sales, implying approximately 50% annual growth at the midpoint versus 2025.
High Patient Impact and Large Addressable Market
XDEMVY has treated over 0.5 million patients since launch against an estimated 25 million Americans with Demodex blepharitis (management cites penetration well under 10%), indicating substantial upside.
Commercial Momentum and Awareness Gains
Unaided patient awareness of Demodex/XDEMVY rose from ~2% to ~25%, payer coverage exceeds 90% across commercial, Medicare and Medicaid, and weekly refills are trending in the low-to-mid teens toward a projected steady-state refill rate of ~20%.
Product-Line Profitability and Strong Margins
Management states XDEMVY is profitable at the product line level; company expects gross margins of approximately 93% (2026 guidance) and long-term gross-to-net discount settling in the ~43%-45% range.
Healthy Balance Sheet and Financial Flexibility
Cash, cash equivalents and marketable securities of approximately $418 million at year-end 2025 to support scaling and pipeline advancement.
Pipeline Advancement with Clear Development Plans
Advancing TP-04 (ocular rosacea) Phase II initiated Dec 2025 with topline data expected 1H 2027; TP-05 (Lyme disease prevention) Phase II planned to start in Q2 2026 (~700 participants) with topline data expected 1H 2027; prior data for TP-05 showed >95% tick-killing within 24 hours in a prior trial.
Target to Reach Blockbuster Scale
Company raised peak U.S. sales conviction for XDEMVY to exceed $2 billion based on current uptake trends, low current penetration, expanding screening/use cases and continued commercial execution.
Focused and Funded Commercial Investments
Planned incremental 2026 investments include ~15-20 new key account leaders and continued DTC/patient education (approx. $80M planned marketing spend), expected to deepen prescribing and conversion.
Negative Updates
High Operating Expenses and Near-Term Profitability Pressure
Total operating expenses for 2025 were $522.3 million—exceeding 2025 net sales of $451.4M—indicating company-level profitability remains a work in progress and requiring continued operating leverage as revenue scales.
Large Gross-to-Net Discount
Reported gross-to-net discounts of ~44% in Q4 2025 and ~45% for the full year; company expects long-term gross-to-net to settle in the 43%-45% range, materially reducing realized revenue per unit.
Near-Term Seasonality and Q1 Headwinds
Management expects Q1 2026 revenues to be flat to slightly below Q4 2025 due to deductible resets, increased out-of-pocket costs, holidays, medical meetings and weather disruptions; this will also temporarily increase gross-to-net in Q1.
Dependence on New-Patient (NRx) Dynamics
XDEMVY remains primarily driven by new prescriptions (NRx), making growth susceptible to seasonal disruptions and events (conferences, weather) until steady-state refill behavior (~20%) is achieved.
Significant Continued Investment Needs
2026 guidance includes SG&A of $545M-$565M and R&D of $115M-$135M (including $40M and $20M in stock-based comp respectively), plus Phase II costs (TP-04 $7M-$10M; TP-05 $25M-$30M), which will keep near-term cash burn and expense elevated.
Uncertainties for Ex-U.S. Expansion and Timing
Ex-U.S. opportunities (Europe, Japan, China) are promising but subject to pricing/reimbursement differences, regulatory timelines (e.g., TP-03 regional paths) and other market-specific dynamics; management did not give definitive timing for international contribution to peak sales.
Company Guidance
Management provided full‑year 2026 guidance calling for net product sales of $670–700 million (implying >$230 million of incremental sales and roughly 50% growth at the midpoint versus FY2025 sales of $451.4 million; Q4 2025 was $151.7 million), while noting revenue won’t be linear (Q1 expected flat to slightly below Q4’25 due to deductible resets and higher gross‑to‑net, then strong Q2, more tempered Q3 and robust Q4). They expect long‑run gross‑to‑net of about 43–45% (Q4’25 was ~44%), gross margin ~93%, SG&A $545–565 million (including ~$40 million stock‑based comp, ~$80 million of DTC/XDEMVY marketing and ~15–20 new key account leaders), R&D $115–135 million (including ~$20 million SBC) with the TP‑04 Phase II budget $7–10 million and TP‑05 Phase II ~$25–30 million, year‑end cash of ~ $418 million, product‑line profitability for XDEMVY today, a steady‑state refill rate target of ~20% (current weekly refills low–mid teens), and an expectation of increasing operating leverage toward company‑level profitability.Tarsus Pharmaceuticals Financial Statement Overview
Summary
Strong revenue acceleration and very high gross margins support improving fundamentals, and the balance sheet is strengthened by eliminating debt. Offsetting this, the company remains unprofitable with ongoing cash burn and negative free cash flow, keeping execution and financing risk in focus.Income Statement
Revenue has accelerated sharply (up 9.5% in 2024 and 23.3% in 2025), and gross margins are consistently very high (~91–96%), signaling strong product-level economics. However, the company remains unprofitable: net losses are still meaningful (2025 net margin about -14.7%), though profitability is improving versus 2023–2024 as losses narrowed materially. Overall, the income statement reflects strong top-line momentum and excellent gross profitability, offset by ongoing operating losses.56
Neutral
Balance Sheet
The balance sheet looks solid and de-risked: total debt fell from ~$72.5M in 2024 to $0 in 2025, and equity increased to ~$343.4M on ~$562.2M of assets. Prior years showed only modest leverage (debt-to-equity ~0.10–0.32), but returns on equity were negative due to net losses. Strength is the elimination of debt and growing equity base; weakness is that shareholder returns remain negative until profitability is achieved.74
Positive
Cash Flow
Cash generation remains a key pressure point: operating cash flow and free cash flow are negative in 2022–2025, with 2025 operating cash flow around -$12.5M and free cash flow around -$22.3M. The cash burn improved dramatically in 2025 versus 2023–2024, but free cash flow growth was sharply negative in 2025 (worse than 2024), showing volatility in burn levels. Overall, cash flow is improving but still not self-funding, which keeps financing risk in focus.42
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 451.36M | 182.95M | 17.45M | 25.82M | 57.03M |
| Gross Profit | 420.68M | 170.13M | 15.85M | 24.86M | 54.95M |
| EBITDA | -53.61M | -106.48M | -131.67M | -59.70M | -13.46M |
| Net Income | -66.42M | -115.55M | -135.89M | -62.09M | -13.83M |
Balance Sheet | |||||
| Total Assets | 562.16M | 376.99M | 265.49M | 227.86M | 178.91M |
| Cash, Cash Equivalents and Short-Term Investments | 417.27M | 291.38M | 227.44M | 217.03M | 171.81M |
| Total Debt | 93.64M | 72.45M | 30.22M | 20.21M | 1.89M |
| Total Liabilities | 218.73M | 152.46M | 68.50M | 34.96M | 12.18M |
| Stockholders Equity | 343.43M | 224.53M | 196.99M | 192.90M | 166.73M |
Cash Flow | |||||
| Free Cash Flow | -22.31M | -84.59M | -123.00M | -49.54M | 3.16M |
| Operating Cash Flow | -12.45M | -83.03M | -117.49M | -49.03M | 3.75M |
| Investing Cash Flow | -42.12M | -199.19M | 140.60M | -144.63M | -586.00K |
| Financing Cash Flow | 143.39M | 154.66M | 130.18M | 93.99M | 21.00K |
Tarsus Pharmaceuticals Technical Analysis
Positive
75.52
Price Trends
72.34
Positive
73.25
Positive
60.25
Positive
Market Momentum
0.77
Negative
62.90
Neutral
72.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TARS, the sentiment is Positive. The current price of 75.52 is above the 20-day moving average (MA) of 66.76, above the 50-day MA of 72.34, and above the 200-day MA of 60.25, indicating a bullish trend. The MACD of 0.77 indicates Negative momentum. The RSI at 62.90 is Neutral, neither overbought nor oversold. The STOCH value of 72.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TARS.
Tarsus Pharmaceuticals Risk Analysis
Tarsus Pharmaceuticals disclosed 80 risk factors in its most recent earnings report. Tarsus Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tarsus Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $3.35B | -192.78 | -9.30% | ― | 129.21% | 80.35% | |
63 Neutral | $2.90B | -28.02 | -8.11% | ― | -84.07% | -157.71% | |
62 Neutral | $3.21B | -46.92 | -23.39% | ― | 182.44% | 47.21% | |
55 Neutral | $3.36B | -7.13 | -44.44% | ― | ― | -5.30% | |
53 Neutral | $1.91B | -2.47 | -59.54% | ― | -32.98% | -18.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $2.54B | -11.12 | -34.78% | ― | ― | -34.96% |
* Healthcare Sector Average
TARS
Tarsus Pharmaceuticals
75.52
32.80
76.78%
DNLI
Denali Therapeutics
21.18
5.98
39.34%
ARQT
Arcutis Biotherapeutics
26.97
14.14
110.21%
BEAM
Beam Therapeutics
28.46
3.36
13.39%
IRON
Disc Medicine
66.62
12.29
22.62%
RXRX
Recursion Pharmaceuticals
3.67
-2.92
-44.31%
Tarsus Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board Changes
Tarsus Pharmaceuticals Adds Industry Veteran to Board
Positive
Feb 18, 2026
On February 18, 2026, Tarsus Pharmaceuticals expanded its board from seven to eight members and appointed veteran biopharmaceutical executive David E. I. Pyott, former chairman and CEO of Allergan, as a Class III director, effective immediately. Pyott was simultaneously named chair of the Board’s Commercial Committee and a member of its Nominating and Compensation Committees, with the Board deeming him independent under Nasdaq and SEC standards.
Pyott, known for transforming Allergan from a $1 billion eye-care company into a $7 billion global specialty pharmaceutical and medical device leader, joins Tarsus as it scales XDEMVY and advances a pipeline in eye care and related specialties. His appointment, supported by a standard non-employee director cash and equity package and an indemnification agreement in line with other Tarsus directors, signals a bid to bolster commercial execution and long-term growth strategy at a pivotal phase for the company.
The most recent analyst rating on (TARS) stock is a Hold with a $68.00 price target. To see the full list of analyst forecasts on Tarsus Pharmaceuticals stock, see the TARS Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.